Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Development and evaluation of a tool to optimise inhaler selection prior to hospital discharge following an exacerbation of COPD.

Price E. et al, (2024), ERJ open research, 10, 10 - 2024

Early Video Assisted Thoracoscopic Surgery (VATS) or Intrapleural Enzyme Therapy (IET) in Pleural Infection - A Feasibility Randomized Controlled Trial (The Third Multicenter Intrapleural Sepsis Trial - MIST-3).

Bedawi EO. et al, (2023), American journal of respiratory and critical care medicine

Platform adaptive trial of novel antivirals for early treatment of COVID-19 In the community (PANORAMIC): protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe disease.

Gbinigie O. et al, (2023), BMJ open, 13

The randomised thoracoscopic talc poudrage+indwelling pleural catheters versus thoracoscopic talc poudrage only in malignant pleural effusion trial (TACTIC): study protocol for a randomised controlled trial

Dipper A. et al, (2023), BMJ Open Respiratory Research, 10, e001682 - e001682

Antibiotic review kit for hospitals (ARK-Hospital): a stepped-wedge cluster-randomised controlled trial

Llewelyn MJ. et al, (2023), The Lancet Infectious Diseases, 23, 207 - 221

Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial

Butler CC. et al, (2023), The Lancet, 401, 281 - 293

Molnupiravir Plus Usual Care Versus Usual Care Alone as Early Treatment for Adults with COVID-19 at Increased Risk of Adverse Outcomes (PANORAMIC): Preliminary Analysis from the United Kingdom Randomised, Controlled Open-Label, Platform Adaptive Trial

Butler C. et al, (2022)

Antibiotic Review Kit for Hospitals (ARK-Hospital): a stepped wedge cluster randomised controlled trial

Llewelyn MJ. et al, (2022)

Role of thoracic ultrasonography in pleurodesis pathways for malignant pleural effusions (SIMPLE): an open-label, randomised controlled trial

Psallidas I. et al, (2022), The Lancet Respiratory Medicine, 10, 139 - 148

Pleural Fluid Has Pro-Growth Biological Properties Which Enable Cancer Cell Proliferation

Asciak R. et al, (2021), Frontiers in Oncology, 11

Patient-derived malignant pleural mesothelioma cell cultures: a tool to advance biomarker-driven treatments

Kanellakis NI. et al, (2020), Thorax, 75, 1004 - 1008

Prospective validation of the RAPID clinical risk prediction score in adult patients with pleural infection: the PILOT study

Corcoran JP. et al, (2020), European Respiratory Journal, 56, 2000130 - 2000130

Antibiotic Review Kit for Hospitals (ARK-Hospital): study protocol for a stepped-wedge cluster-randomised controlled trial

Walker AS. et al, (2019), Trials, 20

Cost-effectiveness of intrapleural use of tissue plasminogen activator and DNase in pleural infection: evidence from the MIST2 randomised controlled trial.

Luengo-Fernandez R. et al, (2019), The European respiratory journal, 54

Early specialist palliative care on quality of life for malignant pleural mesothelioma: a randomised controlled trial

Brims F. et al, (2019), Thorax, 74, 354 - 361

Randomised Ambulatory Management of Primary Pneumothorax (RAMPP): protocol of an open-label, randomised controlled trial

Hallifax R. et al, (2019), BMJ Open Respiratory Research, 6, e000403 - e000403

Biological effect of tissue plasminogen activator (t-PA) and DNase intrapleural delivery in pleural infection patients.

Kanellakis NI. et al, (2019), BMJ open respiratory research, 6

THE BIOLOGICAL EFFECT OF TISSUE PLASMINOGEN (T-PA) ACTIVATOR AND DNASE INTRAPLEURAL DELIVERY IN PLEURAL INFECTION PATIENTS

Kanellakis NI. et al, (2018), THORAX, 73, A243 - A243

The patient perspective of treatment for Malignant Pleural Effusion (MPE)- results of a pilot service-evaluation questionnaire.

Seymour J. et al, (2018), EUROPEAN RESPIRATORY JOURNAL, 52

Development and validation of response markers to predict survival and pleurodesis success in patients with malignant pleural effusion (PROMISE): a multicohort analysis

Psallidas I. et al, (2018), The Lancet Oncology, 19, 930 - 939

Load More

Include forthcoming?